Compositions of midodrine and methods of using the same
This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, a pharmaceutically acceptable salt thereof, or a combination therefore that can be administered to a human subject in need thereof in a supine position. The disclosure also provides pharmaceutical compositions which can be administered once-a-day. This disclosure further provides pharmaceutical compositions comprising an extended release composition and providing a delayed release period between about 30 min to about 12 hours.
1. A method of treating a subject in need thereof, comprising administering to the subject a composition comprising:
(a) a delayed release composition comprising a delayed release agent; and
(b) an extended release composition comprising (i) an effective amount of an active agent selected from midodrine, a pharmaceutically acceptable salt of midodrine, desglymidodrine, a pharmaceutically acceptable salt of desglymidodrine, or a combination thereof, and (ii) a rate controlling agent;
wherein the subject has a disorder selected from the group consisting of: orthostatic hypertension; postural orthostatic tachycardia syndrome (POTS); dysautonomia; symptoms of chronic orthostatic hypotension corresponding to autonomic failure associated with Bradbury-Eggleston syndrome, Shy-Drager syndrome, diabetes mellitus disease, and Parkinson's disease; and retrograde ejaculation.
2. The method of claim 1 , wherein the disorder is orthostatic hypertension.
3. The method of claim 1 , wherein the disorder is postural orthostatic tachycardia syndrome (POTS).
4. The method of claim 1 , wherein release of the active agent is delayed for about 1 hour to about 12 hours.
5. The method of claim 4 , wherein release of the active agent is delayed for about 8 hours to about 12 hours.
6. The method of claim 4 , wherein no more than 10% of the active agent is released in the first 8 hours after administration.
7. The method of claim 4 , wherein the method reduces the incidence of supine hypertension in the subject.
8. The method of claim 4 , wherein the composition is administered before the subject's normal period of sleep at night; and
wherein the delay of release of the active agent overlaps the subject's normal period of sleep or the subject's normal period of being in a supine position.
9. The method of claim 8 , wherein the composition is administered less than 4 hours before the subject goes to sleep.
10. The method of claim 1 , wherein the composition is administered to the subject in a supine position.
11. The method of claim 1 , wherein the composition is in the form of an extended release tablet, a multiparticulate drug delivery, an oral suspension, a powder for oral suspension, a granule for oral suspension, a tablet for oral suspension, a gastroretentive drug delivery system, or any combination thereof.
12. The method of claim 1 , wherein release of the active agent is extended for about 4 hours to about 14 hours.
13. The method of claim 1 , wherein the subject's plasma level of desglymidodrine is at least about 3 ng/mL for a duration of at least about 6 hours after administration of a single dose of the composition.
14. The method of claim 1 , wherein a single dose of the composition comprises the active agent in an amount of about 4 mg to about 150 mg.
15. The method of claim 1 , wherein the delayed release agent is in the form of a coating.
16. The method of claim 1 , wherein the delayed release agent is selected from the group consisting of: ethyl acrylate-methacrylic acid copolymers, polymethacrylate polymer, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, hypromellose, ethyl cellulose, polyvinyl alcohol, and combinations thereof.
17. The method of claim 1 , wherein the extended release composition comprises an extended release coating comprising the active agent and the rate controlling agent or an extended release matrix comprising the active agent and the rate controlling agent.
18. A method of treating postural orthostatic tachycardia syndrome (POTS) in a subject in need thereof, comprising administering to the subject a single dose of a composition comprising an effective amount of an active agent selected from midodrine, a pharmaceutically acceptable salt of midodrine, desglymidodrine, or a pharmaceutically acceptable salt of desglymidodrine,
wherein release of the active agent is delayed for about 1 hour to about 12 hours.
19. The method of claim 18 , wherein the composition may be administered to the subject in a supine position.
20. The method of claim 18 , wherein release of the active agent is extended for about 4 hours to about 14 hours.